<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220426054667N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-07-02</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of a diet based on vegetable and dairy protein in patients with liver cirrhosis</public_title>
      <acronym></acronym>
      <scientific_title>The effect of a diet based on vegetable and dairy protein on serum levels of inflammatory biomarkers and oxidative stress in patients with liver cirrhosis: a randomized controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-06-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69983</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients were randomly assigned to two groups using permuted block randomization with size 2, whose random sequence is generated using RAS software, including the intervention group (receiving a diet based on vegetable and dairy protein) and the control group (receiving a standard isocaloric diet).</study_design>
      <phase>N/A</phase>
      <hc_freetext>Liver Cirrhosis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: A diet based on vegetable and dairy protein. Based on the latest guidelines, in this diet, energy will be calculated 1/3 times REE (using the Harris-Benedict equation), protein will be 1/2 gram per kilogram of body weight, fat will be 30% of total calories, and carbohydrate will be 50-55% of total calories. Then, the required amounts of each food group will be determined, and based on that, a menu of 3 meals and 4 snacks will be prepared and presented to the patient. Patients will follow the prescribed diet for 12 weeks. Patients also will be educated about food alternatives. The protein requirement in this diet will be provided from bread and cereals, vegetables, legumes, soy and soy milk, nuts, and dairy products. Intervention 2: Control group: Standard diet. Based on the latest guidelines, in this diet, energy will be calculated 1/3 times REE (using the Harris-Benedict equation), protein will be 1/2 gram per kilogram of body weight, fat will be 30% of total calories, and carbohydrate will be 50-55% of total calories. Then, the required amounts of each food group will be determined, and based on that, a menu of 3 meals and 4 snacks will be prepared and presented to the patient. Patients will follow the prescribed diet for 12 weeks. Patients also will be educated about food alternatives. The protein requirement in this diet will be provided from bread and cereals, vegetables, legumes, all kinds of meat, eggs, dairy, and nuts.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Due to the confidentiality of the participants' information, it is not possible to publish it</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Somayyeh Asghari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>NO. 44., Shahid Hojjat Doost Ave., Naderi St., Keshavarz Blvd</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1416643931</zip>
        <telephone>0098 21 889900285</telephone>
        <email>asghari.nut@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Somayyeh Asghari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 44, Shahid Hojjat Doost Ave., Naderi St., Keshavarz Blvd</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1416643931</zip>
        <telephone>0098 21 889900285</telephone>
        <email>asghari.nut@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Having liver cirrhosis with a doctor's diagnosis for at least 6 months
Age range from 30 to 60 years
Willingness to participate in the study</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Model for End-Stage Liver Disease (MELD) score greater than 18 or Child-Pugh Class C
Active gastrointestinal bleeding
Serum creatinine above 1.5 mg/dl during the last month
Consumption of alcohol and tobacco during the last 6 months
Pregnancy and lactation
Suffering from diabetes, pulmonary diseases, psychological disorders, hepatocellular carcinoma and other cancers, heart failure, acute viral hepatitis, cholestatic cirrhosis, autoimmune cirrhosis, other autoimmune diseases, hyperuricemia, musculoskeletal diseases
Taking corticosteroids and immunosuppressive medications</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K74.6</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other and unspecified cirrhosis of liver</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: A diet based on vegetable and dairy protein. Based on the latest guidelines, in this diet, energy will be calculated 1/3 times REE (using the Harris-Benedict equation), protein will be 1/2 gram per kilogram of body weight, fat will be 30% of total calories, and carbohydrate will be 50-55% of total calories. Then, the required amounts of each food group will be determined, and based on that, a menu of 3 meals and 4 snacks will be prepared and presented to the patient. Patients will follow the prescribed diet for 12 weeks. Patients also will be educated about food alternatives. The protein requirement in this diet will be provided from bread and cereals, vegetables, legumes, soy and soy milk, nuts, and dairy products.</i_keyword>
      <i_keyword>Control group: Standard diet. Based on the latest guidelines, in this diet, energy will be calculated 1/3 times REE (using the Harris-Benedict equation), protein will be 1/2 gram per kilogram of body weight, fat will be 30% of total calories, and carbohydrate will be 50-55% of total calories. Then, the required amounts of each food group will be determined, and based on that, a menu of 3 meals and 4 snacks will be prepared and presented to the patient. Patients will follow the prescribed diet for 12 weeks. Patients also will be educated about food alternatives. The protein requirement in this diet will be provided from bread and cereals, vegetables, legumes, all kinds of meat, eggs, dairy, and nuts.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Weight. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Digital scale.</prim_outcome>
      <prim_outcome>Height. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Stadiometer.</prim_outcome>
      <prim_outcome>Body Mass Index (BMI). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Body weight (kilogram) divided by the square of height (meter).</prim_outcome>
      <prim_outcome>Mid Arm Circumference (MAC). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Tape.</prim_outcome>
      <prim_outcome>Triceps skin fold (TSF). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Caliper.</prim_outcome>
      <prim_outcome>Middle Arm Muscle Circumference (MAMC). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: MAC – (3.1416 × TSF) formula.</prim_outcome>
      <prim_outcome>Interleukin 6. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: ELISA.</prim_outcome>
      <prim_outcome>Tumor necrosis factor alpha (TNF-α). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: ELISA.</prim_outcome>
      <prim_outcome>High-sensitivity C-reactive protein (hsCRP). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Immunoturbidometry.</prim_outcome>
      <prim_outcome>Malondialdehyde (MDA). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Spectrophotometry.</prim_outcome>
      <prim_outcome>Total antioxidant capacity (TAC). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Spectrophotometry.</prim_outcome>
      <prim_outcome>Total bilirubin. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Photometric.</prim_outcome>
      <prim_outcome>Prothrombin time (PT). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Biochemical kit.</prim_outcome>
      <prim_outcome>Model for End-Stage Liver Disease score. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: The Model for End-Stage Liver Disease score is calculated using serum bilirubin, serum creatinine, and International Normalized Ratio (INR) and is given by the formula: 9.57 × loge (creatinine) + 3.78 × loge (total bilirubin) + 11.2 × loge (International Normalized Ratio) + 6.43.</prim_outcome>
      <prim_outcome>Total oxidant status (TOS). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Spectrophotometry.</prim_outcome>
      <prim_outcome>Creatinine. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Jaafe/colorimetric.</prim_outcome>
      <prim_outcome>International Normalized Ratio (INR). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: [patient PT (s)/MNPT (s)] ISI Formula.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-04-19</approval_date>
        <contact_name>Research Ethics Committees of School of Medicine- Tehran University of Medical Sciences</contact_name>
        <contact_address>Room 605, Sixth Floor, Central Building of Tehran University of Medical Sciences, Qods Street, Keshavarz Blvd. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
